ScreenerHero

CLN Celon Pharma S.A.

GPW · PL · Healthcare · Drug Manufacturers - Specialty & Generic · celonpharma.com
18.84PLN+0.75%Mkt Cap: 257.24M $P/E: 9.24

Celon Pharma S.A., an integrated pharmaceutical company, engages in the research, manufacture, and marketing of specialised generic products. The company provides drugs to treat cancers, neurological diseases, diabetes, …

Industry Peers

Drug Manufacturers - Specialty & Generic
Screen all
MRK
Merck KGaA
$64.30BUSDP/E 25.0
TAK
Takeda Pharmaceutical Company Limited
$56.90BUSD
TEVA
Teva Pharmaceutical Industries Limited
$46.26BUSDP/E 66.1
HLN
Haleon plc
$38.79BUSDP/E 18.0
ZTS
Zoetis Inc.
$29.51BUSDP/E 11.7
ZOE
Zoetis Inc.
$28.27BUSDP/E 12.1
UTHR
United Therapeutics Corporation - Common Stock
$23.23BUSDP/E 19.4
VTRS
Viatris Inc. - Common Stock
$20.22BUSD
SOBI
Swedish Orphan Biovitrum AB (publ)
$14.14BUSDP/E 110.6
NBIX
Neurocrine Biosciences, Inc. - Common Stock
$14.55BUSDP/E 21.0
IPN
Ipsen S.A.
$12.60BUSDP/E 22.8
ELAN
Elanco Animal Health Incorporated
$11.25BUSD
RDY
Dr. Reddy's Laboratories Limited
$10.26BUSDP/E 28.0
KRK
Krka, d. d.
$8.59BUSDP/E 19.2
AMRX
Amneal Pharmaceuticals, Inc. - Class A Common Stock
$7.07BUSDP/E 42.3
ALKS
Alkermes plc - Ordinary Shares
$7.00BUSDP/E 109.9
HIMS
Hims & Hers Health, Inc.
$6.92BUSD
LNTH
Lantheus Holdings, Inc. - Common Stock
$6.53BUSDP/E 23.9
KNSA
Kiniksa Pharmaceuticals International, plc - Class A Ordinary Shares
$5.83BUSDP/E 76.6
INDV
Indivior Pharmaceuticals, Inc. - Common Stock
$4.21BUSDP/E 12.8

Key Statistics

Company
Market Cap257.24M USD
Enterprise Value278.85M USD
Revenue (TTM)65.25M USD
Gross Profit50.06M USD
Net Income (TTM)-20.10M USD
Revenue/Share4.92 PLN
Last Price18.84 PLN
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees560
CountryPL
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ISINPLCLNPH00015
Valuation
P/E (Trailing)9.24
P/E (Forward)11.69
PEG—
EV/EBITDA46.12
EV/Revenue4.27
P/S3.91
P/B1.85
EPS (TTM)2.04
EPS (Forward)1.60
52W Range
18.0015% of range23.50
52W High23.50 PLN
52W Low18.00 PLN
Profitability
Gross Margin76.71%
Oper. Margin-17.03%
EBITDA Margin9.27%
Profit Margin41.46%
ROE-21.85%
ROA-17.35%
Growth
Revenue Growth-0.40%
Earnings Growth—
Cash Flow & Leverage
Operating CF6.04M USD
CapEx (TTM)—
FCF Margin-19.13%
FCF Yield-4.85%
Net Debt23.78M USD
Net Debt/EBITDA3.93
Balance Sheet
Debt/Equity25.76
Current Ratio1.76
Quick Ratio1.38
Book Value/Sh10.10 PLN
Cash/Share0.64 PLN
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 PLN
Div. Yield0.00%
5Y Avg Yield0.29%
Payout Ratio0.00%
Ex-Div DateJun 27, 2024
Pay Date—
Analyst Consensus
Rating—
Target (Mean)20.38 PLN
Upside (mean)+8.2%
Target Range16.00 PLN – 25.20 PLN
16.00+8.2% to mean25.20
# Analysts5
Ownership
Shares Out.53.91M
Float23.82M
Insiders55.70%
Institutions18.27%
Technical
SMA 5020.95 (-10.1%)
SMA 20020.96 (-10.1%)
Beta0.63
S&P 52W Chg14.58%
Avg Vol (30d)17.09K
Avg Vol (10d)16.14K
Technical Indicators
RSI (14)28.2
MACD-0.6864
MACD Signal-0.4774
MACD Hist.-0.2090
BB Upper22.88 PLN
BB Middle20.38 PLN
BB Lower17.87 PLN
BB Width24.61%
ATR (14)0.6489 PLN
Vol Ratio (20d)0.56x